In the News
Statins compared for non-HDL cholesterol levels in patients with diabetes
Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes
An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
MKSAP quiz: Treating diabetes and atherosclerotic disease
This month's quiz asks readers to evaluate a 59-year-old man with type 2 diabetes who had an atherosclerotic stroke one year ago. Medications are aspirin, metformin, candesartan, and rosuvastatin.
Spotlight on diabetes after COVID-19
A cohort study in U.S. veterans and a retrospective analysis in Germany found higher risk for incident diabetes in patients who had had COVID-19.
Paternal metformin use associated with major birth defects
A prospective registry-based study in Denmark found that offspring of men who filled one or more prescriptions for metformin during the three months of developing fertilizing sperm were more likely to have a birth defect, while insulin and sulfonylureas were not associated with increased risk.
Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class
The results of this individual-patient data meta-analysis suggest that angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers should be first-line antihypertensive agents in patients with prediabetes, an ACP Journal Club commentary said.